NNNN קפיטליזציה חשבונאית Anbio

The diagnostics sector is considered a classic defensive asset with stable demand regardless of economic turmoil. The price action of Anbio Biotechnology (NNNN), whose revenues are based on laboratory testing, is currently at 0.04. Stable production capacity and a lack of equipment depreciation support the business, although strict FDA oversight and pricing pressure in the rapid-test segment create certain margin risks.

The equity value dynamics on the balance sheet reflect the resource base of Anbio Biotechnology (NNNN), creating a foundation for scaling the production of portable diagnostic systems. This indicator measures the difference between all assets and liabilities, demonstrating the actual value of net assets; its steady growth confirms the efficiency of capital management and the financial stability of Anbio Biotechnology (NNNN) when implementing innovative medical solutions.